{"protocolSection":{"identificationModule":{"nctId":"NCT01774721","orgStudyIdInfo":{"id":"A7471050"},"secondaryIdInfos":[{"id":"DP312804","type":"OTHER","domain":"Pfizer"}],"organization":{"fullName":"Pfizer","class":"INDUSTRY"},"briefTitle":"ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.","officialTitle":"ARCHER 1050: A RANDOMIZED, OPEN-LABEL, PHASE 3, EFFICACY AND SAFETY STUDY OF DACOMITINIB (PF-00299804) VERSUS GEFITINIB FOR THE FIRST LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN SUBJECTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) ACTIVATING MUTATION(S)"},"statusModule":{"statusVerifiedDate":"2023-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-05-09","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2016-07-29","type":"ACTUAL"},"completionDateStruct":{"date":"2022-01-27","type":"ACTUAL"},"studyFirstSubmitDate":"2013-01-21","studyFirstSubmitQcDate":"2013-01-21","studyFirstPostDateStruct":{"date":"2013-01-24","type":"ESTIMATED"},"resultsFirstSubmitDate":"2018-03-29","resultsFirstSubmitQcDate":"2018-03-29","resultsFirstPostDateStruct":{"date":"2018-10-26","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-02-06","lastUpdatePostDateStruct":{"date":"2023-11-14","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Pfizer","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This is a multinational, multicenter, randomized, open-label, Phase 3 study comparing the efficacy and safety of treatment with dacomitinib (PF-00299804) to treatment with gefitinib in patients with locally advanced or metastatic non-small cell lung cancer, with epidermal growth factor receptor EGFR-activating mutation (s). Analyses of primary objective (Progression Free Survival) will be done as defined in the protocol.","detailedDescription":"452 patients were randomized in a 1:1 ratio between dacomitinib (PF-00299804 ) vs. gefitinib."},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer With EGFR-Activating Mutations"],"keywords":["first-line","locally advanced or metastatic","non-small cell lung cancer","epidermal growth factor receptor","EGFR","ARCHER","mutation","dacomitinib","PF-00299804"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":452,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Dacomitinib (PF-00299804)","type":"EXPERIMENTAL","description":"Dacomitinib (PF-00299804) is provided as 45 mg tablets, continuous oral daily dosing.","interventionNames":["Drug: Dacomitinib (PF-00299804)"]},{"label":"gefitinib","type":"ACTIVE_COMPARATOR","description":"Gefitinib is provided as 250 mg tablets, continuous oral daily dosing.","interventionNames":["Drug: Gefitinib"]}],"interventions":[{"type":"DRUG","name":"Dacomitinib (PF-00299804)","description":"Dacomitinib (PF-00299804) 45 mg tablets, continuous oral daily dosing.","armGroupLabels":["Dacomitinib (PF-00299804)"],"otherNames":["Dacomitinib"]},{"type":"DRUG","name":"Gefitinib","description":"Gefitinib 250 mg tablets, continuous oral daily dosing.","armGroupLabels":["gefitinib"],"otherNames":["Iressa"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review","description":"PFS: time from randomization to date of progression of disease (PD) as determined by IRC review as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria or death due to any cause, whichever occurred first. PD: \\>=20% increase in sum of diameters of target lesions (TLs), referring smallest sum on study, sum must be an absolute increase of \\>=5 mm, appearance of \\>=1 new lesions; unequivocal progression of existing non TLs. Overall tumor burden increased sufficiently to merit discontinuation of therapy. In presence of stable disease (did not achieve partial response, complete response or PD) or partial response (\\>=30% decrease under baseline of sum of diameters of all target measurable lesions, short diameter used in the sum for target nodes, longest diameter used in sum for all other target lesions) in target disease; for new lesions: appearance of any new unequivocal malignant lesion indicated PD.","timeFrame":"Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)"}],"secondaryOutcomes":[{"measure":"Overall Survival (OS)","description":"OS was defined as the time from randomization to the date of death for any cause. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive. OS (month)=\\[death date or last known alive date - randomization date + 1\\]/30.4375.","timeFrame":"From randomization until death or last date known as alive, up to 45 months"},{"measure":"OS at 30 Months (OS30m)","description":"OS30m was defined as the probability of a participant being alive at 30 months from date of randomization.","timeFrame":"Up to 30 months from date of randomization"},{"measure":"Progression Free Survival (PFS) Based on Investigator Assessment","description":"PFS: time from randomization to date of PD as determined by investigator assessment as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria or death due to any cause, whichever occurred first. PD for target lesions: 20% increase in sum of diameters of target measurable lesions above smallest sum observed, with minimum absolute increase of 5 mm; for non-target lesions: unequivocal progression of pre-existing lesions. Overall tumor burden increased sufficiently to merit discontinuation of therapy. In presence of stable disease (did not achieve partial response, complete response or PD) or partial response (\\>=30% decrease under baseline of sum of diameters of all target measurable lesions, short diameter used in the sum for target nodes, longest diameter used in sum for all other target lesions) in target disease; for new lesions: appearance of any new unequivocal malignant lesion indicated PD.","timeFrame":"Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)"},{"measure":"Number of Participants With Best Overall Response (BOR) Based on IRC Review","description":"BOR for CR/PR:\\>=1 objective status (OBS) of CR/PR documented before PD; SD:\\>=1 OBS of stable documented \\>=8 weeks (wks) post treatment \\& before PD, not qualifying as CR/PR; PD:OBS of PD within 12 wks treatment, not qualifying as CR/PR/SD; indeterminate:PD not documented within 12 wks post treatment \\& no other response category applies. RECIST v1.1, CR:disappearance of all target lesions (TLs), non TLs;any pathological lymph nodes (LN) must reduce in short axis to \\<10 mm; normalization of tumour marker level, for non TL all LN must be non-pathological in size (\\<10 mm short axis); PR:\\>=30% decrease in sum of diameters of TLs, referring baseline sum diameters. SD:neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, referring smallest sum diameters on study. PD:\\>=20% increase in sum of diameters of TLs, referring smallest sum on study, sum must be an absolute increase of \\>=5 mm, appearance of \\>=1 new lesions;unequivocal progression of existing non TLs.","timeFrame":"Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression (up to 48 months)"},{"measure":"Number of Participants With Best Overall Response (BOR) Based on Investigator Assessment","description":"BOR for CR/PR:\\>=1 objective status (OBS) of CR/PR documented before PD; SD:\\>=1 OBS of stable documented \\>=8 weeks (wks) post treatment \\& before PD, not qualifying as CR/PR; PD:OBS of PD within 12 wks treatment, not qualifying as CR/PR/SD; indeterminate:PD not documented within 12 wks post treatment \\& no other response category applies. RECIST v1.1, CR:disappearance of all target lesions (TLs), non TLs;any pathological lymph nodes (LN) must reduce in short axis to \\<10 mm; normalization of tumour marker level, for non TL all LN must be non-pathological in size (\\<10 mm short axis); PR:\\>=30% decrease in sum of diameters of TLs, referring baseline sum diameters. SD:neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, referring smallest sum diameters on study. PD:\\>=20% increase in sum of diameters of TLs, referring smallest sum on study, sum must be an absolute increase of \\>=5 mm, appearance of \\>=1 new lesions;unequivocal progression of existing non TLs.","timeFrame":"Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression (up to 48 months)"},{"measure":"Duration of Response (DoR)","description":"DoR was defined as time from first documentation of objective response(CR or PR, whichever occurred first)to date of PD/death from any cause, whichever occurred first. CR: disappearance of all target lesions (TLs), non TLs; any pathological lymph nodes (LN) must reduce in short axis to \\<10 mm; normalization of tumour marker level, for non TL all LN must be non-pathological in size (\\<10 mm short axis); PR:\\>=30% decrease in sum of diameters of TLs, referring baseline sum diameters. PD:\\>=20% increase in sum of diameters of TLs, referring smallest sum on study, sum must be an absolute increase of \\>=5 mm, appearance of \\>=1 new lesions; unequivocal progression of existing non TLs. DoR was recorded based on IRC review and investigator's assessment and summarized for subgroup of participants with objective disease response.","timeFrame":"Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)"},{"measure":"Objective Response Rate (ORR) Based on IRC Review","description":"Percentage of participants with a BOR of either CR or PR based on IRC review recorded from the start of treatment until disease progression based on RECIST v1.1. CR: disappearance of all target lesions (TLs), non TLs; any pathological lymph nodes (LN) must reduce in short axis to \\<10 mm; normalization of tumour marker level, for non TL all LN must be non-pathological in size (\\<10 mm short axis); PR:\\>=30% decrease in sum of diameters of TLs, referring baseline sum diameters. PD:\\>=20% increase in sum of diameters of TLs, referring smallest sum on study, sum must be an absolute increase of \\>=5 mm, appearance of \\>=1 new lesions; unequivocal progression of existing non TLs.","timeFrame":"Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression (up to 48 months)"},{"measure":"Objective Response Rate (ORR) Based on Investigator Assessment","description":"Percentage of participants with a BOR of either CR or PR based on investigator assessment recorded from the start of treatment until disease progression based on RECIST v1.1. CR: disappearance of all target lesions (TLs), non TLs; any pathological lymph nodes (LN) must reduce in short axis to \\<10 mm; normalization of tumour marker level, for non TL all LN must be non-pathological in size (\\<10 mm short axis); PR:\\>=30% decrease in sum of diameters of TLs, referring baseline sum diameters. PD:\\>=20% increase in sum of diameters of TLs, referring smallest sum on study, sum must be an absolute increase of \\>=5 mm, appearance of \\>=1 new lesions; unequivocal progression of existing non TLs.","timeFrame":"Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression (up to 48 months)"},{"measure":"Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":"An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.AEs included both serious and non- serious adverse events. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were events between first dose of study drug and up to 28-35 days after last dose that were absent before treatment or that worsened relative to pretreatment state.","timeFrame":"From randomization until death or last date known as alive, up to 91 months"},{"measure":"Number of Participants With Laboratory Test Abnormalities of Grade 3 or Higher Severity Based on NCI CTCAE Version 4.03: Biochemistry and Haematology","description":"Parameters included anaemia, activated partial thromboplastin time, haemoglobin, international normalized ratio, lymphocyte count, lymphopenia, neutrophils (absolute), platelets, prothrombin time and white blood cells. Biochemistry parameters included alanine aminotransferase (increased), alkaline phosphatase (increased), aspartate aminotransferase (increased), bilirubin (total), creatinine (increased), hypercalcaemia, hyperglycaemia, hyperkalaemia, hypermagnesaemia, hypernatraemia, hypoalbuminaemia, hypocalcaemia, hypoglycaemia, hypokalaemia, hypomagnesaemia, hyponatraemia. Test abnormalities were graded by AEs according to the Common Terminology Criteria for Adverse Events(NCI CTCAE) version 4.03 as Grade 1=mild; Grade 2=moderate; Grade 3=severe; Grade 4=life-threatening; Grade 5=death related to AE. Only categories with at least 1 participant with abnormality are reported in this outcome measure.","timeFrame":"From randomization until death or last date known as alive, up to 61 months"},{"measure":"Number of Participants With Laboratory Test Abnormalities: Urinalysis","description":"Urinalysis parameter included urine protein, urine blood/haemoglobin, urine glucose and urine sediment. Test abnormalities was defined as deviation from normal range (higher or lower). Normal range of 24-hour urine protein test: less than 150 mg of protein per day, urine glucose: 0 to 0.8 mmol/L (millimole per liter), urine protein: 0 to 20 mg/dL (milligrams per deciliter). Urine blood/haemoglobin abnormality was defined as presence and absence of blood/haemoglobin in urine of participants. Urine sediment abnormality was defined as the presence of any bacteria, casts, crystals, and epithelial cells. Only categories with at least 1 participant with abnormality are reported in this outcome measure.","timeFrame":"From randomization until death or last date known as alive, up to 61 months"},{"measure":"Number of Participants With Clinically Significant Abnormalities in Vital Signs","description":"Criteria for vital signs abnormalities: postbaseline pulse rate less than (\\<) 50 beats per minute (bpm) or greater than (\\>)130 bpm and maximum increase from baseline in pulse rate \\>=30 bpm and maximum decrease from baseline in pulse rate \\<=30 bpm. Systolic blood pressure (BP) of maximum increase from baseline (MIB) \\>=40 millimeters of mercury (mmHg), maximum decrease from baseline (MDB) in systolic blood pressure =\\<60 mmHg. Diastolic blood pressure of MIB \\>=20 mmHg and MDB in diastolic blood pressure \\>-40 and =\\<-20 mm Hg. And MDB in diastolic BP\\<=-40 mmHg. Only categories with at least 1 participant with abnormality are reported in this outcome measure.","timeFrame":"From randomization until death or last date known as alive, up to 61 months"},{"measure":"Number of Participants With Clinically Significant Abnormality in Electrocardiogram (ECG)","description":"ECG parameters included corrected QT interval using Bazett's formula (QTcB) and corrected QT interval using Fridericia's formula (QTcF). ECG criteria for abnormality: absolute value 450 - \\<480 msec, 480 - \\<500 msec, \\>=500msec. The number of participants with potentially clinically significant ECG findings at any visit were reported.","timeFrame":"From randomization until death or last date known as alive, up to 61 months"},{"measure":"Number of Participants With Maximum Relative Decrease From Baseline >20% in Left Ventricular Ejection Fraction (LVEF)","description":"An ejection fraction (EF) was the volumetric fraction of blood ejected from a ventricle of the heart with each heartbeat; it was a measure of the pumping efficiency of the heart. The EF of the left heart, known as the left ventricular ejection fraction, was a measure of the efficiency of pumping into the body's systemic circulation.","timeFrame":"From baseline up to 7 days of Cycle 4 (up to 91 days)"},{"measure":"Health Related Quality of Life (HRQOL): Time to Deterioration (TTD) in Pain, Dyspnea, Fatigue or Cough","description":"HRQOL was measured by standardized questionnaires (European Organization for Research and Treatment of Cancer (EORTC)) quality of life questionnaires (OLQ-C30) and its lung cancer module (QLQ-LC13). TTD in pain (chest, arm/shoulder), dyspnea, fatigue or cough was defined as time between baseline and first occurrence of increase in score of 10 points or greater from baseline in any of these 4 symptoms for at least two consecutive cycles. For those who had not shown deterioration, the data was censored at the last date when the participants completed an assessment for pain, dyspnea, fatigue or cough.","timeFrame":"Baseline until the end of treatment (up to 48 months)"},{"measure":"Overall Mean Scores of Euro Quality of Life-5 Dimension Visual Analog Scale (EQ-5D VAS)","description":"The Euro Quality of Life-5 dimension (EQ-5D) is a brief self-administered, validated reliable generic health status instrument. EQ-5D general health status can also be measured by a visual analog scale (EQ-5D VAS). EQ-5D VAS measures the participant's self-rated health status on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state).","timeFrame":"From Cycle 1 Day 1 up to 48 months"},{"measure":"Maximum Observed Plasma Concentration (Cmax) of Dacomitinib and Its Metabolite PF-05199265","description":"Cmax was defined as maximum observed plasma concentration and can be observed directly from data.","timeFrame":"Pre-dose and 2, 4, 6, 8, and 24 hours post-dose on Cycle 2 Day 1 (Day 29)"},{"measure":"Time to Reach Maximum Observed Plasma Concentration (Tmax) of Dacomitinib and Its Metabolite PF-05199265","description":"Tmax was defined as time to first occurrence of Cmax and can be observed directly from data as time of first occurrence.","timeFrame":"Pre-dose and 2, 4, 6, 8, and 24 hours post-dose (sample collection time points had window of +/- 10% of nominal time) on Cycle 2 Day 1 (Day 29)"},{"measure":"Area Under the Plasma Concentration-Time Curve From Time Zero (0) to End of Dosing Interval (AUCtau) of Dacomitinib and Its Metabolite PF-05199265","description":"AUCtau was defined as area under the plasma concentration-time curve over dosing interval tau and was determined by Linear/Log trapezoidal method.","timeFrame":"Pre-dose and 2, 4, 6, 8, and 24 hours post-dose on Cycle 2 Day 1 (Day 29)"},{"measure":"Averaged Plasma Concentration at Steady State (Cavg) of Dacomitinib and Its Metabolite PF-05199265","description":"Cavg was defined as averaged plasma concentration at steady state, and was calculated as AUCtau/tau.","timeFrame":"Pre-dose and 2, 4, 6, 8, and 24 hours post-dose on Cycle 2 Day 1 (Day 29)"},{"measure":"Minimum Observed Plasma Concentration (Cmin) of Dacomitinib and Its Metabolite PF-05199265","description":"Cmin was defined as minimum observed plasma concentration and can be observed directly from data.","timeFrame":"Pre-dose and 2, 4, 6, 8, and 24 hours post-dose on Cycle 2 Day 1 (Day 29)"},{"measure":"Fluctuation Coefficient Between Trough and Peak Plasma Concentration (DF) of Dacomitinib and Its Metabolite PF-05199265","description":"Fluctuation coefficient between trough and peak plasma concentration was determined as Cmax-Ctrough divided by Cavg, where Cmax was the maximum observed concentration within the dosing interval, Ctrough was the observed concentration prior to dose administration and Cavg was averaged plasma concentration at steady state.","timeFrame":"Pre-dose and 2, 4, 6, 8, and 24 hours post-dose on Cycle 2 Day 1 (Day 29)"},{"measure":"Apparent Clearance (CL) of Dacomitinib","description":"Drug clearance was a quantitative measure of the rate at which a drug substance was removed from the blood (rate at which a drug is metabolized or eliminated by normal biological processes).","timeFrame":"Pre-dose and 2, 4, 6, 8, and 24 hours post-dose on Cycle 2 Day 1 (Day 29)"},{"measure":"Pre-dose Plasma Concentrations (Ctrough) of Dacomitinib and Its Metabolite PF-05199265","description":"Trough plasma concentration was defined as the measured concentration at the end of a dosing interval at steady state (taken directly before next administration).","timeFrame":"Pre-dose on Day 1 of Cycle 2, 3, 4, 5 and 6"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Evidence of histo or cytopathology confirmed, advanced NSCLC (with known histology) with the presence of EGFR-activating mutation (exon 19 deletion or the L858R mutation in exon 21).\n* It is acceptable for subjects with the presence of the exon 20 T790M mutation together with either EGFR-activating mutation (exon 19 deletion or the L858R mutation in exon 21) to be included in this study\n* No prior treatment with systemic therapy for locally advanced or metastatic NSCLC. Minimum of 12 months disease free interval between completion of neoadjuvant/adjuvant systemic therapy and recurrence of NSCLC\n* Adequate tissue sample must be available for central analyses.\n* Adequate renal, hematologic, liver function.\n* ECOG PS of 0-1.\n* Radiologically measurable disease.\n\nExclusion Criteria:\n\n* Any evidence of mixed histology that includes elements of small cell or carcinoid lung cancer.\n* Any other mutation other than exon 19 deletion or L858R in exon 21, with or without the presence of the exon 20 T790M mutation.\n* Any history of brain metastases or leptomeningeal metastases.\n* Any previous anti-cancer systemic treatment of early, locally advanced, or metastatic NSCLC.\n* Any surgery(not including minor procedures such as lymph node biopsy), palliative radiotherapy or pleurodesis within 2 weeks of baseline assessments\n* Any clinically significant gastrointestinal abnormalities that may impair intake, transit or absorption of the study drug.\n* Current enrollment in another therapeutic clinical study.\n* History of, or currently suspected, diffuse non-infectious pneumonitis or interstitial lung disease\n* Uncontrolled medical disorders.\n* Prior malignancy and concurrent malignancy except for non melanoma skin cancer or in-situ cervical cancer with no evidence of active disease.\n* Use of narrow therapeutic index drugs that are CYP2D6 substrates from screening to randomization.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"99 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Pfizer CT.gov Call Center","affiliation":"Pfizer","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Beijing","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"city":"Changchun","country":"China","geoPoint":{"lat":43.88,"lon":125.32278}},{"city":"Changsha","country":"China","geoPoint":{"lat":28.19874,"lon":112.97087}},{"city":"Chengdu","country":"China","geoPoint":{"lat":30.66667,"lon":104.06667}},{"city":"Chongqing","country":"China","geoPoint":{"lat":29.56026,"lon":106.55771}},{"city":"Fuzhou","country":"China","geoPoint":{"lat":26.06139,"lon":119.30611}},{"city":"Guangzhou","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"city":"Hangzhou","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"city":"Hefei","country":"China","geoPoint":{"lat":31.86389,"lon":117.28083}},{"city":"Nanning","country":"China","geoPoint":{"lat":22.81667,"lon":108.31667}},{"city":"Shanghai","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"city":"Shenyang","country":"China","geoPoint":{"lat":41.79222,"lon":123.43278}},{"city":"Tianjin","country":"China","geoPoint":{"lat":39.14222,"lon":117.17667}},{"city":"Wuhan","country":"China","geoPoint":{"lat":30.58333,"lon":114.26667}},{"city":"Wuxi","country":"China","geoPoint":{"lat":31.56887,"lon":120.28857}},{"city":"Hong Kong","country":"Hong Kong","geoPoint":{"lat":22.27832,"lon":114.17469}},{"city":"Shatin","country":"Hong Kong","geoPoint":{"lat":22.38333,"lon":114.18333}},{"city":"Catania","country":"Italy","geoPoint":{"lat":37.49223,"lon":15.07041}},{"city":"Lecco","country":"Italy","geoPoint":{"lat":45.85589,"lon":9.39704}},{"city":"Livorno","country":"Italy","geoPoint":{"lat":43.54427,"lon":10.32615}},{"city":"Meldola","country":"Italy","geoPoint":{"lat":44.12775,"lon":12.0626}},{"city":"Milan","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"city":"Napoli","country":"Italy","geoPoint":{"lat":40.87618,"lon":14.5195}},{"city":"Perugia","country":"Italy","geoPoint":{"lat":43.1122,"lon":12.38878}},{"city":"Ravenna","country":"Italy","geoPoint":{"lat":44.41344,"lon":12.20121}},{"city":"Roma","country":"Italy","geoPoint":{"lat":44.99364,"lon":11.10642}},{"city":"Trento","country":"Italy","geoPoint":{"lat":46.06787,"lon":11.12108}},{"city":"Viterbo","country":"Italy","geoPoint":{"lat":42.41937,"lon":12.1056}},{"city":"Hokkaido","state":"Asahikawa","country":"Japan"},{"city":"Kashiwa","state":"Chiba","country":"Japan","geoPoint":{"lat":35.86224,"lon":139.97732}},{"city":"Matsuyama","state":"Ehime","country":"Japan","geoPoint":{"lat":33.83916,"lon":132.76574}},{"city":"Yokohama","state":"Kanagawa","country":"Japan","geoPoint":{"lat":35.43333,"lon":139.65}},{"city":"Tokyo","state":"Koto-ku","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"city":"Sakai","state":"Osaka","country":"Japan","geoPoint":{"lat":34.58216,"lon":135.46653}},{"city":"Sayama","state":"Osaka","country":"Japan","geoPoint":{"lat":34.51685,"lon":135.56298}},{"city":"Sunto-gun","state":"Shizouka","country":"Japan"},{"city":"Chuo-Ku","state":"Tokyo","country":"Japan"},{"city":"Gdansk","country":"Poland","geoPoint":{"lat":54.35227,"lon":18.64912}},{"city":"Olsztyn","country":"Poland","geoPoint":{"lat":53.78376,"lon":20.49272}},{"city":"Poznan","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"city":"Warsaw","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"city":"Seoul","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"city":"Ávila","country":"Spain","geoPoint":{"lat":40.65724,"lon":-4.69951}},{"city":"Barcelona","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"city":"Bilbao","country":"Spain","geoPoint":{"lat":43.26271,"lon":-2.92528}},{"city":"Cáceres","country":"Spain","geoPoint":{"lat":39.47649,"lon":-6.37224}},{"city":"Córdoba","country":"Spain","geoPoint":{"lat":37.89155,"lon":-4.77275}},{"city":"Donostia / San Sebastian","country":"Spain","geoPoint":{"lat":43.31283,"lon":-1.97499}},{"city":"Las Palmas","country":"Spain","geoPoint":{"lat":28.58232,"lon":-16.16555}},{"city":"Madrid","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"city":"Málaga","country":"Spain","geoPoint":{"lat":36.72016,"lon":-4.42034}},{"city":"Seville","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}}]},"referencesModule":{"references":[{"pmid":"39360943","type":"DERIVED","citation":"Pu X, Li J, Zhang B, Zhang J, K Mok TS, Nakagawa K, Rosell R, Cheng Y, Zhou X, Miglorino MR, Niho S, Lee KH, Corral J, Pluzanski A, Li J, Linke R, Pan F, Tang Y, Tan W, Wu L. Efficacy in patients with EGFR-positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: post hoc analyses from ARCHER 1050. Future Oncol. 2024;20(37):2971-2982. doi: 10.1080/14796694.2024.2404762. Epub 2024 Oct 3."},{"pmid":"34120312","type":"DERIVED","citation":"Li J, Nickens D, Wilner K, Tan W. Evaluation of the Effect of Proton Pump Inhibitors on the Efficacy of Dacomitinib and Gefitinib in Patients with Advanced Non-Small Cell Lung Cancer and EGFR-Activating Mutations. Oncol Ther. 2021 Dec;9(2):525-539. doi: 10.1007/s40487-021-00156-2. Epub 2021 Jun 13."},{"pmid":"33721611","type":"DERIVED","citation":"Cheng Y, Mok TS, Zhou X, Lu S, Zhou Q, Zhou J, Du Y, Yu P, Liu X, Hu C, Lu Y, Zhang Y, Lee KH, Nakagawa K, Linke R, Wong CH, Tang Y, Zhu F, Wilner KD, Wu YL. Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050). Lung Cancer. 2021 Apr;154:176-185. doi: 10.1016/j.lungcan.2021.02.025. Epub 2021 Feb 23."},{"pmid":"33331989","type":"DERIVED","citation":"Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Chawla A, Rosell R, Corral J, Migliorino MR, Pluzanski A, Noonan K, Tang Y, Pastel M, Wilner KD, Wu YL. Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. Drugs. 2021 Feb;81(2):257-266. doi: 10.1007/s40265-020-01441-6."},{"pmid":"31313942","type":"DERIVED","citation":"Corral J, Mok TS, Nakagawa K, Rosell R, Lee KH, Migliorino MR, Pluzanski A, Linke R, Devgan G, Tan W, Quinn S, Wang T, Wu YL. Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer. Future Oncol. 2019 Aug;15(24):2795-2805. doi: 10.2217/fon-2019-0299. Epub 2019 Jul 17."},{"pmid":"31050691","type":"DERIVED","citation":"Nagano T, Tachihara M, Nishimura Y. Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer. Drugs Today (Barc). 2019 Apr;55(4):231-236. doi: 10.1358/dot.2019.55.4.2965337."},{"pmid":"29864379","type":"DERIVED","citation":"Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Lee M, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Wu YL. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. J Clin Oncol. 2018 Aug 1;36(22):2244-2250. doi: 10.1200/JCO.2018.78.7994. Epub 2018 Jun 4."},{"pmid":"28958502","type":"DERIVED","citation":"Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017 Nov;18(11):1454-1466. doi: 10.1016/S1470-2045(17)30608-3. Epub 2017 Sep 25."},{"pmid":"26768165","type":"DERIVED","citation":"Ramalingam SS, O'Byrne K, Boyer M, Mok T, Janne PA, Zhang H, Liang J, Taylor I, Sbar EI, Paz-Ares L. Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials. Ann Oncol. 2016 Mar;27(3):423-9. doi: 10.1093/annonc/mdv593. Epub 2016 Jan 13."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\\_trials/trial\\_data\\_and\\_results/data\\_requests.","url":"https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"The study completed enrollment on 25 Mar 2015 with 452 participants randomized, 227 participants to the dacomitinib arm and 225 participants to the gefitinib arm. After the last data cutoff (DCO) date of 13 May 2019, 11 participants remained in the study to continue dacomitinib treatment. All 11 participants were discontinued from the study by last participant last visit (LPLV) on 27 Jan 2022.","groups":[{"id":"FG000","title":"Dacomitinib","description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."},{"id":"FG001","title":"Gefitinib","description":"Participants received 250 mg of gefitinib tablets orally once daily in each treatment cycle of 28 days, for maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"227"},{"groupId":"FG001","numSubjects":"225"}]},{"type":"Treated","achievements":[{"groupId":"FG000","numSubjects":"227"},{"groupId":"FG001","numSubjects":"224"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"227"},{"groupId":"FG001","numSubjects":"225"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"133"},{"groupId":"FG001","numSubjects":"152"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"14"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"7"}]},{"type":"Did not meet eligibility criteria","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Other reasons and patients who completed the 48-month follow-up period","reasons":[{"groupId":"FG000","numSubjects":"58"},{"groupId":"FG001","numSubjects":"49"}]},{"type":"Study terminated by sponsor","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Disease progression","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"ITT Population included all participants who were randomized, with study treatment assignment designated according to initial randomization, regardless of whether participants received study treatment or received a different treatment from that to which they were randomized.","groups":[{"id":"BG000","title":"Dacomitinib","description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."},{"id":"BG001","title":"Gefitinib","description":"Participants received 250 mg of gefitinib tablets orally once daily in each treatment cycle of 28 days, for maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"227"},{"groupId":"BG001","value":"225"},{"groupId":"BG002","value":"452"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"61.2","spread":"11.26"},{"groupId":"BG001","value":"60.9","spread":"10.17"},{"groupId":"BG002","value":"61.1","spread":"10.72"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"146"},{"groupId":"BG001","value":"125"},{"groupId":"BG002","value":"271"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"81"},{"groupId":"BG001","value":"100"},{"groupId":"BG002","value":"181"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"227"},{"groupId":"BG001","value":"225"},{"groupId":"BG002","value":"452"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"170"},{"groupId":"BG001","value":"176"},{"groupId":"BG002","value":"346"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"56"},{"groupId":"BG001","value":"49"},{"groupId":"BG002","value":"105"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review","description":"PFS: time from randomization to date of progression of disease (PD) as determined by IRC review as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria or death due to any cause, whichever occurred first. PD: \\>=20% increase in sum of diameters of target lesions (TLs), referring smallest sum on study, sum must be an absolute increase of \\>=5 mm, appearance of \\>=1 new lesions; unequivocal progression of existing non TLs. Overall tumor burden increased sufficiently to merit discontinuation of therapy. In presence of stable disease (did not achieve partial response, complete response or PD) or partial response (\\>=30% decrease under baseline of sum of diameters of all target measurable lesions, short diameter used in the sum for target nodes, longest diameter used in sum for all other target lesions) in target disease; for new lesions: appearance of any new unequivocal malignant lesion indicated PD.","populationDescription":"Intent to treat (ITT) Population included all randomized participants, with study treatment assignment designated according to initial randomization, regardless of whether participants received study treatment or a different treatment from that to which they were randomized.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)","groups":[{"id":"OG000","title":"Dacomitinib","description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."},{"id":"OG001","title":"Gefitinib","description":"Participants received 250 mg of gefitinib tablets orally once daily in each treatment cycle of 28 days, for maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"225"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.7","lowerLimit":"11.1","upperLimit":"16.6"},{"groupId":"OG001","value":"9.2","lowerLimit":"9.1","upperLimit":"11.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"1-sided stratified log-rank test","paramType":"Hazard Ratio (HR)","paramValue":"0.589","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.469","ciUpperLimit":"0.739","estimateComment":"Based on stratified Cox regression model"}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS was defined as the time from randomization to the date of death for any cause. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive. OS (month)=\\[death date or last known alive date - randomization date + 1\\]/30.4375.","populationDescription":"ITT Population included all randomized participants, with study treatment assignment designated according to initial randomization, regardless of whether participants received study treatment or a different treatment from that to which they were randomized.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From randomization until death or last date known as alive, up to 45 months","groups":[{"id":"OG000","title":"Dacomitinib","description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."},{"id":"OG001","title":"Gefitinib","description":"Participants received 250 mg of gefitinib tablets orally once daily in each treatment cycle of 28 days, for maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"225"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.1","lowerLimit":"29.5","upperLimit":"39.8"},{"groupId":"OG001","value":"27.0","lowerLimit":"24.4","upperLimit":"31.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0077","statisticalMethod":"1-sided stratified log-rank test","paramType":"Hazard Ratio (HR)","paramValue":"0.748","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.591","ciUpperLimit":"0.947","estimateComment":"Based on stratified Cox Regression model"}]},{"type":"SECONDARY","title":"OS at 30 Months (OS30m)","description":"OS30m was defined as the probability of a participant being alive at 30 months from date of randomization.","populationDescription":"ITT Population included all randomized participants, with study treatment assignment designated according to initial randomization, regardless of whether participants received study treatment or a different treatment from that to which they were randomized.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"probability of survival","timeFrame":"Up to 30 months from date of randomization","groups":[{"id":"OG000","title":"Dacomitinib","description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."},{"id":"OG001","title":"Gefitinib","description":"Participants received 250 mg of gefitinib tablets orally once daily in each treatment cycle of 28 days, for maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"225"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.4","lowerLimit":"49.6","upperLimit":"62.7"},{"groupId":"OG001","value":"45.7","lowerLimit":"39.0","upperLimit":"52.2"}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS) Based on Investigator Assessment","description":"PFS: time from randomization to date of PD as determined by investigator assessment as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria or death due to any cause, whichever occurred first. PD for target lesions: 20% increase in sum of diameters of target measurable lesions above smallest sum observed, with minimum absolute increase of 5 mm; for non-target lesions: unequivocal progression of pre-existing lesions. Overall tumor burden increased sufficiently to merit discontinuation of therapy. In presence of stable disease (did not achieve partial response, complete response or PD) or partial response (\\>=30% decrease under baseline of sum of diameters of all target measurable lesions, short diameter used in the sum for target nodes, longest diameter used in sum for all other target lesions) in target disease; for new lesions: appearance of any new unequivocal malignant lesion indicated PD.","populationDescription":"ITT Population included all randomized participants, with study treatment assignment designated according to initial randomization, regardless of whether participants received study treatment or a different treatment from that to which they were randomized.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)","groups":[{"id":"OG000","title":"Dacomitinib","description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."},{"id":"OG001","title":"Gefitinib","description":"Participants received 250 mg of gefitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"225"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.6","lowerLimit":"12.9","upperLimit":"18.4"},{"groupId":"OG001","value":"11.0","lowerLimit":"9.4","upperLimit":"12.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"1-sided stratified log-rank test","paramType":"Hazard Ratio (HR)","paramValue":"0.622","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.497","ciUpperLimit":"0.779","estimateComment":"Based on stratified Cox regression model"}]},{"type":"SECONDARY","title":"Number of Participants With Best Overall Response (BOR) Based on IRC Review","description":"BOR for CR/PR:\\>=1 objective status (OBS) of CR/PR documented before PD; SD:\\>=1 OBS of stable documented \\>=8 weeks (wks) post treatment \\& before PD, not qualifying as CR/PR; PD:OBS of PD within 12 wks treatment, not qualifying as CR/PR/SD; indeterminate:PD not documented within 12 wks post treatment \\& no other response category applies. RECIST v1.1, CR:disappearance of all target lesions (TLs), non TLs;any pathological lymph nodes (LN) must reduce in short axis to \\<10 mm; normalization of tumour marker level, for non TL all LN must be non-pathological in size (\\<10 mm short axis); PR:\\>=30% decrease in sum of diameters of TLs, referring baseline sum diameters. SD:neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, referring smallest sum diameters on study. PD:\\>=20% increase in sum of diameters of TLs, referring smallest sum on study, sum must be an absolute increase of \\>=5 mm, appearance of \\>=1 new lesions;unequivocal progression of existing non TLs.","populationDescription":"ITT Population included all randomized participants, with study treatment assignment designated according to initial randomization, regardless of whether participants received study treatment or a different treatment from that to which they were randomized.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression (up to 48 months)","groups":[{"id":"OG000","title":"Dacomitinib","description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."},{"id":"OG001","title":"Gefitinib","description":"Participants received 250 mg of gefitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"225"}]}],"classes":[{"title":"Complete response","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"4"}]}]},{"title":"Partial response","categories":[{"measurements":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"157"}]}]},{"title":"Stable disease","categories":[{"measurements":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"27"}]}]},{"title":"Progressive disease","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"15"}]}]},{"title":"Indeterminate","categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"22"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Best Overall Response (BOR) Based on Investigator Assessment","description":"BOR for CR/PR:\\>=1 objective status (OBS) of CR/PR documented before PD; SD:\\>=1 OBS of stable documented \\>=8 weeks (wks) post treatment \\& before PD, not qualifying as CR/PR; PD:OBS of PD within 12 wks treatment, not qualifying as CR/PR/SD; indeterminate:PD not documented within 12 wks post treatment \\& no other response category applies. RECIST v1.1, CR:disappearance of all target lesions (TLs), non TLs;any pathological lymph nodes (LN) must reduce in short axis to \\<10 mm; normalization of tumour marker level, for non TL all LN must be non-pathological in size (\\<10 mm short axis); PR:\\>=30% decrease in sum of diameters of TLs, referring baseline sum diameters. SD:neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, referring smallest sum diameters on study. PD:\\>=20% increase in sum of diameters of TLs, referring smallest sum on study, sum must be an absolute increase of \\>=5 mm, appearance of \\>=1 new lesions;unequivocal progression of existing non TLs.","populationDescription":"ITT Population included all randomized participants, with study treatment assignment designated according to initial randomization, regardless of whether participants received study treatment or a different treatment from that to which they were randomized.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression (up to 48 months)","groups":[{"id":"OG000","title":"Dacomitinib","description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."},{"id":"OG001","title":"Gefitinib","description":"Participants received 250 mg of gefitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"225"}]}],"classes":[{"title":"Complete response","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"Partial response","categories":[{"measurements":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"157"}]}]},{"title":"Stable disease","categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"49"}]}]},{"title":"Progressive disease","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"11"}]}]},{"title":"Indeterminate","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DoR)","description":"DoR was defined as time from first documentation of objective response(CR or PR, whichever occurred first)to date of PD/death from any cause, whichever occurred first. CR: disappearance of all target lesions (TLs), non TLs; any pathological lymph nodes (LN) must reduce in short axis to \\<10 mm; normalization of tumour marker level, for non TL all LN must be non-pathological in size (\\<10 mm short axis); PR:\\>=30% decrease in sum of diameters of TLs, referring baseline sum diameters. PD:\\>=20% increase in sum of diameters of TLs, referring smallest sum on study, sum must be an absolute increase of \\>=5 mm, appearance of \\>=1 new lesions; unequivocal progression of existing non TLs. DoR was recorded based on IRC review and investigator's assessment and summarized for subgroup of participants with objective disease response.","populationDescription":"ITT Population included all randomized participants, with study treatment assignment designated according to initial randomization, regardless of whether participants received study treatment or a different treatment from that to which they were randomized.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)","groups":[{"id":"OG000","title":"Dacomitinib","description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."},{"id":"OG001","title":"Gefitinib","description":"Participants received 250 mg of gefitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"225"}]}],"classes":[{"title":"DoR: IRC review","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"161"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.8","lowerLimit":"12.0","upperLimit":"17.4"},{"groupId":"OG001","value":"8.3","lowerLimit":"7.4","upperLimit":"9.2"}]}]},{"title":"DoR: Investigator assessment","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"158"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.9","lowerLimit":"13.8","upperLimit":"17.6"},{"groupId":"OG001","value":"9.2","lowerLimit":"8.2","upperLimit":"11.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Comparison of dacomitinib vs gefitinib based on IRC review","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"1-sided stratified log-rank test","paramType":"Hazard Ratio (HR)","paramValue":"0.403","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.307","ciUpperLimit":"0.529","estimateComment":"Based on stratified Cox regression model"},{"groupIds":["OG000","OG001"],"groupDescription":"Comparison of dacomitinib vs gefitinib based on Investigator assessment","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"1-sided stratified log-rank test","paramType":"Hazard Ratio (HR)","paramValue":"0.545","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.418","ciUpperLimit":"0.711","estimateComment":"Based on stratified Cox regression model"}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR) Based on IRC Review","description":"Percentage of participants with a BOR of either CR or PR based on IRC review recorded from the start of treatment until disease progression based on RECIST v1.1. CR: disappearance of all target lesions (TLs), non TLs; any pathological lymph nodes (LN) must reduce in short axis to \\<10 mm; normalization of tumour marker level, for non TL all LN must be non-pathological in size (\\<10 mm short axis); PR:\\>=30% decrease in sum of diameters of TLs, referring baseline sum diameters. PD:\\>=20% increase in sum of diameters of TLs, referring smallest sum on study, sum must be an absolute increase of \\>=5 mm, appearance of \\>=1 new lesions; unequivocal progression of existing non TLs.","populationDescription":"ITT Population included all randomized participants, with study treatment assignment designated according to initial randomization, regardless of whether participants received study treatment or a different treatment from that to which they were randomized.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression (up to 48 months)","groups":[{"id":"OG000","title":"Dacomitinib","description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."},{"id":"OG001","title":"Gefitinib","description":"Participants received 250 mg of gefitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"225"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.9","lowerLimit":"68.7","upperLimit":"80.4"},{"groupId":"OG001","value":"71.6","lowerLimit":"65.2","upperLimit":"77.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1942","statisticalMethod":"Cochran-Mantel-Haenszel"}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR) Based on Investigator Assessment","description":"Percentage of participants with a BOR of either CR or PR based on investigator assessment recorded from the start of treatment until disease progression based on RECIST v1.1. CR: disappearance of all target lesions (TLs), non TLs; any pathological lymph nodes (LN) must reduce in short axis to \\<10 mm; normalization of tumour marker level, for non TL all LN must be non-pathological in size (\\<10 mm short axis); PR:\\>=30% decrease in sum of diameters of TLs, referring baseline sum diameters. PD:\\>=20% increase in sum of diameters of TLs, referring smallest sum on study, sum must be an absolute increase of \\>=5 mm, appearance of \\>=1 new lesions; unequivocal progression of existing non TLs.","populationDescription":"ITT Population included all randomized participants, with study treatment assignment designated according to initial randomization, regardless of whether participants received study treatment or a different treatment from that to which they were randomized.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression (up to 48 months)","groups":[{"id":"OG000","title":"Dacomitinib","description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."},{"id":"OG001","title":"Gefitinib","description":"Participants received 250 mg of gefitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"225"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.3","lowerLimit":"69.2","upperLimit":"80.8"},{"groupId":"OG001","value":"70.2","lowerLimit":"63.8","upperLimit":"76.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0924","statisticalMethod":"Cochran-Mantel-Haenszel"}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":"An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.AEs included both serious and non- serious adverse events. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were events between first dose of study drug and up to 28-35 days after last dose that were absent before treatment or that worsened relative to pretreatment state.","populationDescription":"Safety analysis set included all participants who received at least 1 dose of study medication, with treatment assignments designated according to actual study treatment received.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From randomization until death or last date known as alive, up to 91 months","groups":[{"id":"OG000","title":"Dacomitinib","description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."},{"id":"OG001","title":"Gefitinib","description":"Participants received 250 mg of gefitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."},{"id":"OG002","title":"Dacomitinib (Ongoing at DCO)","description":"DCO was the protocol-defined cutoff at 48 months from first dosing of the last enrolled participant (13 May 2019). At the DCO, 11 participants were ongoing in the dacomitinib arm and continued study treatment until disease progression, intolerable toxicities, withdrawal, death, or study terminated by sponsor, whichever occurred first. The 11 participants were analyzed for adverse events after LPLV on 27 Jan 2022."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"224"},{"groupId":"OG002","value":"11"}]}],"classes":[{"title":"TEAEs","categories":[{"measurements":[{"groupId":"OG000","value":"226"},{"groupId":"OG001","value":"220"},{"groupId":"OG002","value":"11"}]}]},{"title":"SAEs","categories":[{"measurements":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"53"},{"groupId":"OG002","value":"4"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Laboratory Test Abnormalities of Grade 3 or Higher Severity Based on NCI CTCAE Version 4.03: Biochemistry and Haematology","description":"Parameters included anaemia, activated partial thromboplastin time, haemoglobin, international normalized ratio, lymphocyte count, lymphopenia, neutrophils (absolute), platelets, prothrombin time and white blood cells. Biochemistry parameters included alanine aminotransferase (increased), alkaline phosphatase (increased), aspartate aminotransferase (increased), bilirubin (total), creatinine (increased), hypercalcaemia, hyperglycaemia, hyperkalaemia, hypermagnesaemia, hypernatraemia, hypoalbuminaemia, hypocalcaemia, hypoglycaemia, hypokalaemia, hypomagnesaemia, hyponatraemia. Test abnormalities were graded by AEs according to the Common Terminology Criteria for Adverse Events(NCI CTCAE) version 4.03 as Grade 1=mild; Grade 2=moderate; Grade 3=severe; Grade 4=life-threatening; Grade 5=death related to AE. Only categories with at least 1 participant with abnormality are reported in this outcome measure.","populationDescription":"Safety analysis set included all participants who received at least 1 dose of study medication, with treatment assignments designated according to actual study treatment received.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From randomization until death or last date known as alive, up to 61 months","groups":[{"id":"OG000","title":"Dacomitinib","description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."},{"id":"OG001","title":"Gefitinib","description":"Participants received 250 mg of gefitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"224"}]}],"classes":[{"title":"Anaemia (Grade 3)","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"}]}]},{"title":"Haemoglobin increased(Grade 3)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Lymphopenia (Grade 3)","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"6"}]}]},{"title":"Neutrophil count (absolute) (Grade 3)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"WBC count (Grade 3)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"Alanine aminotransferase increased (Grade 3)","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"26"}]}]},{"title":"Alanine aminotransferase increased (Grade 4)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}]},{"title":"Aspartate aminotransferase increased (Grade 3)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"15"}]}]},{"title":"Aspartate aminotransferase increased (Grade 4)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}]},{"title":"Alkaline phosphatase increased (Grade 3)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"}]}]},{"title":"Bilirubin increased (total) (Grade 3)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"Creatinine increased (Grade 3)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"Hypercalcemia (Grade 3)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Hyperglycemia (Grade 3)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"}]}]},{"title":"Hyperkalemia (Grade 3)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Hyperkalemia (Grade 4)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"Hypermagnesemia (Grade 3)","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"}]}]},{"title":"Hypocalcemia (Grade 3)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"}]}]},{"title":"Hypoglycemia (Grade 3)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"Hypoglycemia (Grade 4)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Hypokalemia (Grade 3)","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"5"}]}]},{"title":"Hypokalemia (Grade 4)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Hypomagnesemia (Grade 3)","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Hyponatremia (Grade 3)","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"}]}]},{"title":"Hyponatremia (Grade 4)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Laboratory Test Abnormalities: Urinalysis","description":"Urinalysis parameter included urine protein, urine blood/haemoglobin, urine glucose and urine sediment. Test abnormalities was defined as deviation from normal range (higher or lower). Normal range of 24-hour urine protein test: less than 150 mg of protein per day, urine glucose: 0 to 0.8 mmol/L (millimole per liter), urine protein: 0 to 20 mg/dL (milligrams per deciliter). Urine blood/haemoglobin abnormality was defined as presence and absence of blood/haemoglobin in urine of participants. Urine sediment abnormality was defined as the presence of any bacteria, casts, crystals, and epithelial cells. Only categories with at least 1 participant with abnormality are reported in this outcome measure.","populationDescription":"Safety analysis set included all participants who received at least 1 dose of study medication, with treatment assignments designated according to actual study treatment received.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From randomization until death or last date known as alive, up to 61 months","groups":[{"id":"OG000","title":"Dacomitinib","description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."},{"id":"OG001","title":"Gefitinib","description":"Participants received 250 mg of gefitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"224"}]}],"classes":[{"title":"High Urine Protein","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"Low Urine Glucose","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"High Urine Blood/Haemoglobin","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Clinically Significant Abnormalities in Vital Signs","description":"Criteria for vital signs abnormalities: postbaseline pulse rate less than (\\<) 50 beats per minute (bpm) or greater than (\\>)130 bpm and maximum increase from baseline in pulse rate \\>=30 bpm and maximum decrease from baseline in pulse rate \\<=30 bpm. Systolic blood pressure (BP) of maximum increase from baseline (MIB) \\>=40 millimeters of mercury (mmHg), maximum decrease from baseline (MDB) in systolic blood pressure =\\<60 mmHg. Diastolic blood pressure of MIB \\>=20 mmHg and MDB in diastolic blood pressure \\>-40 and =\\<-20 mm Hg. And MDB in diastolic BP\\<=-40 mmHg. Only categories with at least 1 participant with abnormality are reported in this outcome measure.","populationDescription":"Safety analysis set included all participants who received at least 1 dose of study medication, with treatment assignments designated according to actual study treatment received.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From randomization until death or last date known as alive, up to 61 months","groups":[{"id":"OG000","title":"Dacomitinib","description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."},{"id":"OG001","title":"Gefitinib","description":"Participants received 250 mg of gefitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"224"}]}],"classes":[{"title":"MIB in systolic BP >=40 mmHg","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"223"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"22"}]}]},{"title":"MDB in systolic BP <=-60 mmHg","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"223"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"MIB in diastolic BP >=20 mmHg","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"223"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"44"}]}]},{"title":"MDB in diastolic BP >-40 and <=-20mmHg","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"223"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"53"}]}]},{"title":"MDB in diastolic BP <=-40 mmHg","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"223"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Maximum post baseline pulse rate >130 bpm","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"226"},{"groupId":"OG001","value":"223"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]},{"title":"Minimum post baseline pulse rate <50 bpm","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"226"},{"groupId":"OG001","value":"223"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}]},{"title":"MIB in pulse rate >=30 bpm","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"223"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"12"}]}]},{"title":"MDB in pulse rate <=-30 bpm","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"223"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"15"}]}]},{"title":"MIB in body weight >=10%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"223"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"42"}]}]},{"title":"MDB in body weight <=-10%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"225"},{"groupId":"OG001","value":"223"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"32"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Clinically Significant Abnormality in Electrocardiogram (ECG)","description":"ECG parameters included corrected QT interval using Bazett's formula (QTcB) and corrected QT interval using Fridericia's formula (QTcF). ECG criteria for abnormality: absolute value 450 - \\<480 msec, 480 - \\<500 msec, \\>=500msec. The number of participants with potentially clinically significant ECG findings at any visit were reported.","populationDescription":"Safety analysis set included all participants who received at least 1 dose of study medication, with treatment assignments designated according to actual study treatment received. Here, \"N\" (number of participants analyzed) signifies participants who were evaluable for this specified outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From randomization until death or last date known as alive, up to 61 months","groups":[{"id":"OG000","title":"Dacomitinib","description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."},{"id":"OG001","title":"Gefitinib","description":"Participants received 250 mg of gefitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"217"},{"groupId":"OG001","value":"7"}]}],"classes":[{"title":"QTcF Criteria: 450-<480","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"}]}]},{"title":"QTcB Criteria: 450-<480","categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"0"}]}]},{"title":"QTcB Criteria: 480-<500","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Maximum Relative Decrease From Baseline >20% in Left Ventricular Ejection Fraction (LVEF)","description":"An ejection fraction (EF) was the volumetric fraction of blood ejected from a ventricle of the heart with each heartbeat; it was a measure of the pumping efficiency of the heart. The EF of the left heart, known as the left ventricular ejection fraction, was a measure of the efficiency of pumping into the body's systemic circulation.","populationDescription":"Safety analysis set included all participants who received at least 1 dose of study medication, with treatment assignments designated according to actual study treatment received. Here \"N\" signifies number of participants who were evaluable for this specified outcome measure.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From baseline up to 7 days of Cycle 4 (up to 91 days)","groups":[{"id":"OG000","title":"Dacomitinib","description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."},{"id":"OG001","title":"Gefitinib","description":"Participants received 250 mg of gefitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"191"},{"groupId":"OG001","value":"199"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"}]}]}]},{"type":"SECONDARY","title":"Health Related Quality of Life (HRQOL): Time to Deterioration (TTD) in Pain, Dyspnea, Fatigue or Cough","description":"HRQOL was measured by standardized questionnaires (European Organization for Research and Treatment of Cancer (EORTC)) quality of life questionnaires (OLQ-C30) and its lung cancer module (QLQ-LC13). TTD in pain (chest, arm/shoulder), dyspnea, fatigue or cough was defined as time between baseline and first occurrence of increase in score of 10 points or greater from baseline in any of these 4 symptoms for at least two consecutive cycles. For those who had not shown deterioration, the data was censored at the last date when the participants completed an assessment for pain, dyspnea, fatigue or cough.","populationDescription":"Patient reported outcomes (PRO) analysis set included all enrolled participants, who started treatment and completed a baseline PRO assessments and at least one post-baseline PRO assessment after the first dose.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline until the end of treatment (up to 48 months)","groups":[{"id":"OG000","title":"Dacomitinib","description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."},{"id":"OG001","title":"Gefitinib","description":"Participants received 250 mg of gefitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"226"},{"groupId":"OG001","value":"222"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","lowerLimit":"2.3","upperLimit":"4.8"},{"groupId":"OG001","value":"6.6","lowerLimit":"3.8","upperLimit":"9.3"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1641","statisticalMethod":"Unstratified Log-rank Test","paramType":"Cox Proportional Hazard","paramValue":"1.173","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.928","ciUpperLimit":"1.483"}]},{"type":"SECONDARY","title":"Overall Mean Scores of Euro Quality of Life-5 Dimension Visual Analog Scale (EQ-5D VAS)","description":"The Euro Quality of Life-5 dimension (EQ-5D) is a brief self-administered, validated reliable generic health status instrument. EQ-5D general health status can also be measured by a visual analog scale (EQ-5D VAS). EQ-5D VAS measures the participant's self-rated health status on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state).","populationDescription":"PRO analysis set included all enrolled participants, who started treatment and completed a baseline PRO assessments and at least one post-baseline PRO assessment after the first dose. Here \"N\" signifies number of participants who were evaluable for this specified outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"units on a scale","timeFrame":"From Cycle 1 Day 1 up to 48 months","groups":[{"id":"OG000","title":"Dacomitinib","description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."},{"id":"OG001","title":"Gefitinib","description":"Participants received 250 mg of gefitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"221"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.3869","lowerLimit":"71.608","upperLimit":"75.166"},{"groupId":"OG001","value":"77.6923","lowerLimit":"75.895","upperLimit":"79.490"}]}]}]},{"type":"SECONDARY","title":"Maximum Observed Plasma Concentration (Cmax) of Dacomitinib and Its Metabolite PF-05199265","description":"Cmax was defined as maximum observed plasma concentration and can be observed directly from data.","populationDescription":"Pharmacokinetic (PK) analysis set included all participants who were treated with dacomitinib with at least 1 measured plasma concentration and were dose-compliant (who received 45 mg dacomitinib daily without interruptions/dose reductions for at least 14 days prior to day of data collection). This outcome measure was planned to be analyzed in Chinese subgroup only.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"nanogram per milliliter (ng/mL)","timeFrame":"Pre-dose and 2, 4, 6, 8, and 24 hours post-dose on Cycle 2 Day 1 (Day 29)","groups":[{"id":"OG000","title":"Dacomitinib","description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"}]}],"classes":[{"title":"Dacomitinib","categories":[{"measurements":[{"groupId":"OG000","value":"84.19","spread":"21.90"}]}]},{"title":"PF-05199265","categories":[{"measurements":[{"groupId":"OG000","value":"12.77","spread":"7.58"}]}]}]},{"type":"SECONDARY","title":"Time to Reach Maximum Observed Plasma Concentration (Tmax) of Dacomitinib and Its Metabolite PF-05199265","description":"Tmax was defined as time to first occurrence of Cmax and can be observed directly from data as time of first occurrence.","populationDescription":"PK analysis set included all participants who were treated with dacomitinib with at least 1 measured plasma concentration and were dose-compliant (who received 45 mg dacomitinib daily without interruptions/dose reductions for at least 14 days prior to day of data collection). This outcome measure was planned to be analyzed in Chinese subgroup only.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"hour","timeFrame":"Pre-dose and 2, 4, 6, 8, and 24 hours post-dose (sample collection time points had window of +/- 10% of nominal time) on Cycle 2 Day 1 (Day 29)","groups":[{"id":"OG000","title":"Dacomitinib","description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"}]}],"classes":[{"title":"Dacomitinib","categories":[{"measurements":[{"groupId":"OG000","value":"4.03","lowerLimit":"2.0","upperLimit":"24.0"}]}]},{"title":"PF-05199265","categories":[{"measurements":[{"groupId":"OG000","value":"6.0","lowerLimit":"0.0","upperLimit":"25.0"}]}]}]},{"type":"SECONDARY","title":"Area Under the Plasma Concentration-Time Curve From Time Zero (0) to End of Dosing Interval (AUCtau) of Dacomitinib and Its Metabolite PF-05199265","description":"AUCtau was defined as area under the plasma concentration-time curve over dosing interval tau and was determined by Linear/Log trapezoidal method.","populationDescription":"PK analysis set included all participants who were treated with dacomitinib with at least 1 measured plasma concentration and were dose-compliant (who received 45 mg dacomitinib daily without interruptions/dose reductions for at least 14 days prior to day of data collection). This outcome measure was planned to be analyzed in Chinese subgroup only.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"nanogram*hour/milliliter (ng*hr/mL)","timeFrame":"Pre-dose and 2, 4, 6, 8, and 24 hours post-dose on Cycle 2 Day 1 (Day 29)","groups":[{"id":"OG000","title":"Dacomitinib","description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"}]}],"classes":[{"title":"Dacomitinib","categories":[{"measurements":[{"groupId":"OG000","value":"1712.08","spread":"413.61"}]}]},{"title":"PF-05199265","categories":[{"measurements":[{"groupId":"OG000","value":"278.47","spread":"163.53"}]}]}]},{"type":"SECONDARY","title":"Averaged Plasma Concentration at Steady State (Cavg) of Dacomitinib and Its Metabolite PF-05199265","description":"Cavg was defined as averaged plasma concentration at steady state, and was calculated as AUCtau/tau.","populationDescription":"PK analysis set included all participants who were treated with dacomitinib with at least 1 measured plasma concentration and were dose-compliant (who received 45 mg dacomitinib daily without interruptions/dose reductions for at least 14 days prior to day of data collection). This outcome measure was planned to be analyzed in Chinese subgroup only.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/mL","timeFrame":"Pre-dose and 2, 4, 6, 8, and 24 hours post-dose on Cycle 2 Day 1 (Day 29)","groups":[{"id":"OG000","title":"Dacomitinib","description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"}]}],"classes":[{"title":"Dacomitinib","categories":[{"measurements":[{"groupId":"OG000","value":"71.33","spread":"17.23"}]}]},{"title":"PF-05199265","categories":[{"measurements":[{"groupId":"OG000","value":"11.60","spread":"6.81"}]}]}]},{"type":"SECONDARY","title":"Minimum Observed Plasma Concentration (Cmin) of Dacomitinib and Its Metabolite PF-05199265","description":"Cmin was defined as minimum observed plasma concentration and can be observed directly from data.","populationDescription":"PK analysis set included all participants who were treated with dacomitinib with at least 1 measured plasma concentration and were dose-compliant (who received 45 mg dacomitinib daily without interruptions/dose reductions for at least 14 days prior to day of data collection). This outcome measure was planned to be analyzed in Chinese subgroup only.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/mL","timeFrame":"Pre-dose and 2, 4, 6, 8, and 24 hours post-dose on Cycle 2 Day 1 (Day 29)","groups":[{"id":"OG000","title":"Dacomitinib","description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"}]}],"classes":[{"title":"Dacomitinib","categories":[{"measurements":[{"groupId":"OG000","value":"60.64","spread":"14.85"}]}]},{"title":"PF-05199265","categories":[{"measurements":[{"groupId":"OG000","value":"10.49","spread":"6.26"}]}]}]},{"type":"SECONDARY","title":"Fluctuation Coefficient Between Trough and Peak Plasma Concentration (DF) of Dacomitinib and Its Metabolite PF-05199265","description":"Fluctuation coefficient between trough and peak plasma concentration was determined as Cmax-Ctrough divided by Cavg, where Cmax was the maximum observed concentration within the dosing interval, Ctrough was the observed concentration prior to dose administration and Cavg was averaged plasma concentration at steady state.","populationDescription":"PK analysis set included all participants who were treated with dacomitinib with at least 1 measured plasma concentration and were dose-compliant (who received 45 mg dacomitinib daily without interruptions/dose reductions for at least 14 days prior to day of data collection). This outcome measure was planned to be analyzed in Chinese subgroup only.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Fluctuation coefficient","timeFrame":"Pre-dose and 2, 4, 6, 8, and 24 hours post-dose on Cycle 2 Day 1 (Day 29)","groups":[{"id":"OG000","title":"Dacomitinib","description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"}]}],"classes":[{"title":"Dacomitinib","categories":[{"measurements":[{"groupId":"OG000","value":"0.2883","spread":"0.1460"}]}]},{"title":"PF-05199265","categories":[{"measurements":[{"groupId":"OG000","value":"0.1105","spread":"0.0827"}]}]}]},{"type":"SECONDARY","title":"Apparent Clearance (CL) of Dacomitinib","description":"Drug clearance was a quantitative measure of the rate at which a drug substance was removed from the blood (rate at which a drug is metabolized or eliminated by normal biological processes).","populationDescription":"PK analysis set included all participants who were treated with dacomitinib with at least 1 measured plasma concentration and were dose-compliant (who received 45 mg dacomitinib daily without interruptions/dose reductions for at least 14 days prior to day of data collection). This outcome measure was planned to be analyzed in Chinese subgroup only.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Liter/hour","timeFrame":"Pre-dose and 2, 4, 6, 8, and 24 hours post-dose on Cycle 2 Day 1 (Day 29)","groups":[{"id":"OG000","title":"Dacomitinib","description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.61","spread":"5.97"}]}]}]},{"type":"SECONDARY","title":"Pre-dose Plasma Concentrations (Ctrough) of Dacomitinib and Its Metabolite PF-05199265","description":"Trough plasma concentration was defined as the measured concentration at the end of a dosing interval at steady state (taken directly before next administration).","populationDescription":"PK analysis set included all participants who were treated with dacomitinib with at least one measured plasma concentration and were dose-compliant. Dose-compliant participants were those who received 45 mg dacomitinib daily without interruptions or dose reductions for at least 14 days prior to the day of data collection. Here, 'Number Analyzed' = participants evaluable for this outcome measure at specified time points.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/mL","timeFrame":"Pre-dose on Day 1 of Cycle 2, 3, 4, 5 and 6","groups":[{"id":"OG000","title":"Dacomitinib","description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"188"}]}],"classes":[{"title":"Cycle 2 Day 1: Dacomitinib","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"176"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"70.24","spread":"27.16"}]}]},{"title":"Cycle 3 Day 1: Dacomitinib","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"68.34","spread":"25.80"}]}]},{"title":"Cycle 4 Day 1: Dacomitinib","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"112"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"68.16","spread":"25.49"}]}]},{"title":"Cycle 5 Day 1: Dacomitinib","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"85"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"64.50","spread":"25.52"}]}]},{"title":"Cycle 6 Day 1: Dacomitinib","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"74"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"61.68","spread":"22.58"}]}]},{"title":"Cycle 2 Day 1: PF-05199265","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"176"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.20","spread":"8.55"}]}]},{"title":"Cycle 3 Day 1: PF-05199265","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"143"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.42","spread":"9.10"}]}]},{"title":"Cycle 4 Day 1: PF-05199265","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"112"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.70","spread":"8.33"}]}]},{"title":"Cycle 5 Day 1: PF-05199265","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"85"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.48","spread":"6.69"}]}]},{"title":"Cycle 6 Day 1: PF-05199265","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"74"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.05","spread":"6.52"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From randomization until death or last date known as alive, up to 91 months","description":"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another participant, or one participant may have experienced both a serious and non-serious event during the study. Safety analysis set included all participants who received at least 1 dose of study medication, with treatment assignments designated according to actual study treatment received.","eventGroups":[{"id":"EG000","title":"Dacomitinib","description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first.","deathsNumAffected":133,"deathsNumAtRisk":227,"seriousNumAffected":69,"seriousNumAtRisk":227,"otherNumAffected":224,"otherNumAtRisk":227},{"id":"EG001","title":"Gefitinib","description":"Participants received 250 mg of gefitinib tablets orally once daily in each treatment cycle of 28 days, for maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first.","deathsNumAffected":152,"deathsNumAtRisk":224,"seriousNumAffected":53,"seriousNumAtRisk":224,"otherNumAffected":217,"otherNumAtRisk":224},{"id":"EG002","title":"Dacomitinib (Ongoing at DCO)","description":"DCO was the protocol-defined cutoff at 48 months from first dosing of the last enrolled participant (13 May 2019). At the DCO, 11 participants were ongoing in the dacomitinib arm and continued study treatment until disease progression, intolerable toxicities, withdrawal, death, or study terminated by sponsor, whichever occurred first. The 11 participants were analyzed for adverse events after LPLV on 27 Jan 2022.","deathsNumAffected":1,"deathsNumAtRisk":11,"seriousNumAffected":4,"seriousNumAtRisk":11,"otherNumAffected":11,"otherNumAtRisk":11}],"seriousEvents":[{"term":"Leukocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Cardiac tamponade","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Arteriosclerosis coronary artery","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Keratitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Gastric ulcer haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Mouth haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Rectal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Haematochezia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Large intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Disease progression","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":227},{"groupId":"EG001","numAffected":12,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Multiple organ dysfunction syndrome","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Liver injury","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Drug-induced liver injury","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Bile duct stone","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":227},{"groupId":"EG001","numAffected":2,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Bronchopulmonary aspergillosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Escherichia urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Facial bones fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Spinal fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Extradural haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Subdural haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":2,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Tibia fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Hepatic enzyme increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":2,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Malnutrition","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":2,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Polymyalgia rheumatica","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Basal cell carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Chronic myeloid leukaemia","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Malignant neoplasm progression","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":2,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Pancreatic carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":3,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Cerebral venous thrombosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Spinal cord compression","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Cognitive disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Post herpetic neuralgia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Suicide attempt","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Ureterolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":227},{"groupId":"EG001","numAffected":2,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":4,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Bronchospasm","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Organising pneumonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Drug eruption","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Decubitus ulcer","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Cholangitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Arthritis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Ligament injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Ligament rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Metastases to meninges","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Cancer pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Nervous system disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Otitis media chronic","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Concussion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":27,"numAtRisk":227},{"groupId":"EG001","numAffected":18,"numAtRisk":224},{"groupId":"EG002","numAffected":5,"numAtRisk":11}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":199,"numAtRisk":227},{"groupId":"EG001","numAffected":125,"numAtRisk":224},{"groupId":"EG002","numAffected":10,"numAtRisk":11}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":99,"numAtRisk":227},{"groupId":"EG001","numAffected":41,"numAtRisk":224},{"groupId":"EG002","numAffected":6,"numAtRisk":11}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":45,"numAtRisk":227},{"groupId":"EG001","numAffected":50,"numAtRisk":224},{"groupId":"EG002","numAffected":3,"numAtRisk":11}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":32,"numAtRisk":227},{"groupId":"EG001","numAffected":29,"numAtRisk":224},{"groupId":"EG002","numAffected":2,"numAtRisk":11}]},{"term":"Mouth ulceration","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":32,"numAtRisk":227},{"groupId":"EG001","numAffected":14,"numAtRisk":224},{"groupId":"EG002","numAffected":3,"numAtRisk":11}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":227},{"groupId":"EG001","numAffected":29,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Aphthous ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":227},{"groupId":"EG001","numAffected":6,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Oral pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":227},{"groupId":"EG001","numAffected":1,"numAtRisk":224},{"groupId":"EG002","numAffected":4,"numAtRisk":11}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":227},{"groupId":"EG001","numAffected":13,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":227},{"groupId":"EG001","numAffected":12,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":227},{"groupId":"EG001","numAffected":14,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":32,"numAtRisk":227},{"groupId":"EG001","numAffected":30,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":227},{"groupId":"EG001","numAffected":27,"numAtRisk":224},{"groupId":"EG002","numAffected":3,"numAtRisk":11}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":227},{"groupId":"EG001","numAffected":20,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":227},{"groupId":"EG001","numAffected":8,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":227},{"groupId":"EG001","numAffected":18,"numAtRisk":224},{"groupId":"EG002","numAffected":3,"numAtRisk":11}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":227},{"groupId":"EG001","numAffected":7,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":227},{"groupId":"EG001","numAffected":14,"numAtRisk":224},{"groupId":"EG002","numAffected":3,"numAtRisk":11}]},{"term":"Paronychia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":140,"numAtRisk":227},{"groupId":"EG001","numAffected":45,"numAtRisk":224},{"groupId":"EG002","numAffected":9,"numAtRisk":11}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":46,"numAtRisk":227},{"groupId":"EG001","numAffected":10,"numAtRisk":224},{"groupId":"EG002","numAffected":3,"numAtRisk":11}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":36,"numAtRisk":227},{"groupId":"EG001","numAffected":29,"numAtRisk":224},{"groupId":"EG002","numAffected":5,"numAtRisk":11}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":227},{"groupId":"EG001","numAffected":20,"numAtRisk":224},{"groupId":"EG002","numAffected":3,"numAtRisk":11}]},{"term":"Rash pustular","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":227},{"groupId":"EG001","numAffected":3,"numAtRisk":224},{"groupId":"EG002","numAffected":2,"numAtRisk":11}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":227},{"groupId":"EG001","numAffected":8,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":67,"numAtRisk":227},{"groupId":"EG001","numAffected":43,"numAtRisk":224},{"groupId":"EG002","numAffected":5,"numAtRisk":11}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":53,"numAtRisk":227},{"groupId":"EG001","numAffected":90,"numAtRisk":224},{"groupId":"EG002","numAffected":7,"numAtRisk":11}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":49,"numAtRisk":227},{"groupId":"EG001","numAffected":84,"numAtRisk":224},{"groupId":"EG002","numAffected":5,"numAtRisk":11}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":227},{"groupId":"EG001","numAffected":20,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":227},{"groupId":"EG001","numAffected":8,"numAtRisk":224},{"groupId":"EG002","numAffected":2,"numAtRisk":11}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":227},{"groupId":"EG001","numAffected":19,"numAtRisk":224},{"groupId":"EG002","numAffected":3,"numAtRisk":11}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":227},{"groupId":"EG001","numAffected":14,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":227},{"groupId":"EG001","numAffected":19,"numAtRisk":224},{"groupId":"EG002","numAffected":3,"numAtRisk":11}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":73,"numAtRisk":227},{"groupId":"EG001","numAffected":58,"numAtRisk":224},{"groupId":"EG002","numAffected":2,"numAtRisk":11}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":25,"numAtRisk":227},{"groupId":"EG001","numAffected":13,"numAtRisk":224},{"groupId":"EG002","numAffected":2,"numAtRisk":11}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":34,"numAtRisk":227},{"groupId":"EG001","numAffected":26,"numAtRisk":224},{"groupId":"EG002","numAffected":5,"numAtRisk":11}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":227},{"groupId":"EG001","numAffected":31,"numAtRisk":224},{"groupId":"EG002","numAffected":2,"numAtRisk":11}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":227},{"groupId":"EG001","numAffected":37,"numAtRisk":224},{"groupId":"EG002","numAffected":3,"numAtRisk":11}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":227},{"groupId":"EG001","numAffected":14,"numAtRisk":224},{"groupId":"EG002","numAffected":2,"numAtRisk":11}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":227},{"groupId":"EG001","numAffected":11,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":227},{"groupId":"EG001","numAffected":11,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":227},{"groupId":"EG001","numAffected":21,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":227},{"groupId":"EG001","numAffected":17,"numAtRisk":224},{"groupId":"EG002","numAffected":2,"numAtRisk":11}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":32,"numAtRisk":227},{"groupId":"EG001","numAffected":33,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":47,"numAtRisk":227},{"groupId":"EG001","numAffected":46,"numAtRisk":224},{"groupId":"EG002","numAffected":5,"numAtRisk":11}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":31,"numAtRisk":227},{"groupId":"EG001","numAffected":29,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":227},{"groupId":"EG001","numAffected":5,"numAtRisk":224},{"groupId":"EG002","numAffected":3,"numAtRisk":11}]},{"term":"Nasal inflammation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":227},{"groupId":"EG001","numAffected":3,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":227},{"groupId":"EG001","numAffected":13,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":227},{"groupId":"EG001","numAffected":12,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Dermatitis acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":112,"numAtRisk":227},{"groupId":"EG001","numAffected":64,"numAtRisk":224},{"groupId":"EG002","numAffected":3,"numAtRisk":11}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":64,"numAtRisk":227},{"groupId":"EG001","numAffected":39,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":53,"numAtRisk":227},{"groupId":"EG001","numAffected":29,"numAtRisk":224},{"groupId":"EG002","numAffected":4,"numAtRisk":11}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":47,"numAtRisk":227},{"groupId":"EG001","numAffected":33,"numAtRisk":224},{"groupId":"EG002","numAffected":3,"numAtRisk":11}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":41,"numAtRisk":227},{"groupId":"EG001","numAffected":26,"numAtRisk":224},{"groupId":"EG002","numAffected":2,"numAtRisk":11}]},{"term":"Palmar-plantar erythrodysaesthesia syndrome","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":33,"numAtRisk":227},{"groupId":"EG001","numAffected":7,"numAtRisk":224},{"groupId":"EG002","numAffected":2,"numAtRisk":11}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":29,"numAtRisk":227},{"groupId":"EG001","numAffected":27,"numAtRisk":224},{"groupId":"EG002","numAffected":4,"numAtRisk":11}]},{"term":"Dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":25,"numAtRisk":227},{"groupId":"EG001","numAffected":9,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Skin fissures","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":227},{"groupId":"EG001","numAffected":7,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Acne","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":227},{"groupId":"EG001","numAffected":13,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":227},{"groupId":"EG001","numAffected":3,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":227},{"groupId":"EG001","numAffected":21,"numAtRisk":224},{"groupId":"EG002","numAffected":2,"numAtRisk":11}]},{"term":"Dry eye","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":227},{"groupId":"EG001","numAffected":8,"numAtRisk":224},{"groupId":"EG002","numAffected":3,"numAtRisk":11}]},{"term":"Angular cheilitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":227},{"groupId":"EG001","numAffected":2,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Folliculitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":227},{"groupId":"EG001","numAffected":4,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":227},{"groupId":"EG001","numAffected":5,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Blood lactate dehydrogenase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":227},{"groupId":"EG001","numAffected":12,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":227},{"groupId":"EG001","numAffected":10,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":227},{"groupId":"EG001","numAffected":8,"numAtRisk":224},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Leukocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Sinus tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":2,"numAtRisk":11}]},{"term":"Corneal erosion","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Eye pruritus","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Keratitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Periorbital oedema","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Trichiasis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":2,"numAtRisk":11}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":2,"numAtRisk":11}]},{"term":"Abdominal pain lower","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Chapped lips","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Glossodynia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Mass","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Hepatic function abnormal","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":2,"numAtRisk":11}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Immune system disorder","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":2,"numAtRisk":11}]},{"term":"Nasal vestibulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":2,"numAtRisk":11}]},{"term":"Gingivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Otitis externa","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Pharyngotonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Skin abrasion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":3,"numAtRisk":11}]},{"term":"Blood albumin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Blood glucose increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Blood potassium decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Blood uric acid increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Eosinophil count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Glomerular filtration rate decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Neutrophil count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Platelet count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Hyperuricaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":2,"numAtRisk":11}]},{"term":"Hyperlipidaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Hypernatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Tetany","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":2,"numAtRisk":11}]},{"term":"Periarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":2,"numAtRisk":11}]},{"term":"Intervertebral disc protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Joint swelling","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Sciatica","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Vertebral artery stenosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Pelvic fluid collection","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Vulvovaginal rash","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":3,"numAtRisk":11}]},{"term":"Nasal mucosal ulcer","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":2,"numAtRisk":11}]},{"term":"Catarrh","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Laryngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Nasal mucosal disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Drug eruption","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Hirsutism","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Nail disorder","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Pain of skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Papule","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Skin ulcer","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Ischaemia","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Deafness","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":227},{"groupId":"EG001","numAffected":0,"numAtRisk":224},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."},"pointOfContact":{"title":"Pfizer ClinicalTrials.gov Call Center","organization":"Pfizer, Inc.","email":"ClinicalTrials.gov_Inquiries@pfizer.com","phone":"1-800-718-1021"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D009362","term":"Neoplasm Metastasis"},{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D009385","term":"Neoplastic Processes"},{"id":"D009369","term":"Neoplasms"},{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"},{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C525726","term":"dacomitinib"},{"id":"D000077156","term":"Gefitinib"}],"ancestors":[{"id":"D011799","term":"Quinazolines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"}]}},"hasResults":true}